So we know about the Galera $150 million deal here. There was a partnering deal for UC and other intestinal diseases between Janssen Biotech (JNJ Subsidiary) and Theravance, $100 million upfront and 900 million in milestones if phase 2 goes well and the drugs get clear for phase 3 and commercialization. We are very low on estimates.

http://www.bioworld.com/content/intestinal-fo...tor-deal-0